Those on the highest 36 mg dose of the medicine on average lost 12.4 per cent of their body weight at 72 weeks ...

Explores Behemoth Labz GLP‑1 nasal formulation's structural design, analytic insights, and intranasal incretin research relevance in preclinical metabolic ...

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

For centuries, the European honeybee has given people honey, wax, propolis, and even venom. Now, scientists are looking ...

Historically, sex-related differences have been underexplored in neurology. It is important to highlight the distinction ...

Different levels of two neuropeptides can turn leafcutter ants into soldiers, farmers, or nurses, highlighting their role in ...

Osteoporosis is a chronic disease mainly prevalent in older people. A hip fracture, its most devastating complication, is associated with a one in five chance of mortality in the first year. This ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

The Revolution of Face Serums in Modern Skincare In the ever-evolving world of skincare, few products have revolutionized personal care routines quite like face serums. These potent, lightweight ...

In a significant step forward for reproductive health, an experimental, hormone-free male birth control pill has successfully passed its first safety trial in humans.

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...